We performed a whole-genome association study of human immunodeficiency virus type 1 (HIV-1) set point among a cohort of African Americans ( ), and an intronic single-nucleotide polymorphism (SNP) in n p 515 the HLA-B gene showed one of the strongest associations. We use a subset of patients to demonstrate that this SNP reflects the effect of the HLA-B*5703 allele, which shows a genome-wide statistically significant association with viral load set point ( ). These analyses therefore confirm a member of the HLA-Ϫ10
to be associated with set point (rs2395029) encodes a nonsynonymous change in the HCP5 gene and is also a tag for HLA-B*5701, which has been shown to be associated with improved early outcomes after exposure to HIV-1 [2, 3] . The other variant that is associated with set point (rs9264942) is 35 kilobases upstream of the HLA-C locus and appears to be tagging a causative variant or variants. A third variant (rs9261174) associated with disease progression is located near the ZNRD1 gene in the major histocompatibility complex (MHC) region, although functional work on this gene
has not yet identified a causal variant. Together, these variants are able to explain ∼14% of the observed variation in outcome after HIV-1 exposure.
A follow-up study investigated the impact of these same single-nucleotide polymorphisms (SNPs) on an HIV-1-positive African American cohort ( ) n p 121 [4] . As was seen in individuals of European ancestry, the HLA-C-associated variant (rs9264942) was again found to be associated with viral load, with the C "highexpression" allele leading to lower viral load. Although no association was observed with the G allele of rs2395029, this allele is rare in African Americans; in people of European ancestry, the allele is in linkage disequilibrium with HLA-B*5701, which is also rare in people of African descent. However, an analysis of the HLA-B alleles present in the region showed an association between HLA-B*57 (comprised predominantly of HLA-B*5703) and favorable virologic outcome.
Although the study described above [4] and others [5, 6] have assessed the impact of variants in African Americans that were first identified in patients of European ancestry, to our knowledge there has not yet been any genome-wide investigation of the most important common variants that influence viral load in patients of primarily African ancestry. Here, we present the first genome-wide association study of determinants of HIV-1 control performed among a non-European population. Using a cohort of African American individuals (n p ), we sought to evaluate the associations previously reported 515 and to discover novel or population-specific genetic variants that are associated with HIV-1 control.
METHODS

Samples.
This study included HIV-1-infected African American adult participants enrolled in either the United States military Department of Defense Human Immunodeficiency Virus Natural History Study (DoD HIV NHS) or the Multicenter AIDS Cohort Study (MACS). This study was approved by local institutional review boards, and each participant provided written, informed consent.
The DoD HIV NHS (http://www.idcrp.org/hiv-natural-history -study.html) is an ongoing, prospective, continuous-enrollment cohort study of consenting military personnel and beneficiaries with HIV infection and includes participants from the Army, Navy/Marines, and Air Force and their dependents. Since 1985, routine HIV testing (by enzyme-linked immunosorbent assay and confirmatory Western blot analysis) has been used to exclude HIV-infected persons from enlisting for military service or from overseas deployment. Periodic testing among active duty members occurs every 1-5 years, resulting in a defined seroconversion window for incident HIV infection. Participants with HIV infection are referred to military medical centers, where they receive evaluation and ongoing care and are invited to enroll as participants in the DoD HIV NHS.
Those who consent to enroll in the DoD HIV NHS are seen every 6 months by an HIV specialist as part of the study, in addition to receiving routine clinical care. Data are collected on demographic characteristics, markers of HIV disease progression, medication use, and clinical events with medical record confirmation. Cells, plasma, and serum are collected at each visit and stored in a central repository.
Information was extracted from the database on HIV-infected African American individuals with р4 years between their last negative and first positive HIV test results, at least 5 million cells stored in the repository, and either 1 viral load measurement taken 3-12 months after seroconversion (n p ) or 2 viral load measurements taken within 3 months to 140 3 years after seroconversion ( ). Ethnicity was self-idenn p 347 tified. The seroconversion date was estimated as the midpoint between the last negative and first positive HIV test results.
The MACS (http://www.statepi.jhsph.edu/macs/macs.html) is an ongoing prospective study of the natural and treated histories of HIV-1 infection among men who have sex with men that is conducted by sites located in Baltimore, Chicago, Pittsburgh, and Los Angeles. A total of 6973 men have been enrolled; 3427 participants were HIV-seronegative at study entry and were tested for seroconversion semiannually by means of enzyme-linked immunosorbent assay, with positive test results confirmed by Western blot analysis. Of the seroincident par- ticipants, African Americans with available DNA and viral load data from before treatment initiation were selected for inclusion in the current study.
Other cohorts referenced in this analysis include HIV-1-infected adult participants of European ancestry in a study performed by the European Center for HIV/AIDS Vaccine Immunology (Euro-CHAVI) and MACS participants who were included in a previous whole-genome association study (n p ) [7] . The Euro-CHAVI cohort represents a consortium 2362 of 8 European cohorts and 1 Australian cohort of patients who agreed to participate in the Host Genetic Core initiative of the Center for HIV/AIDS Vaccine Immunology (CHAVI).
Genotyping. All samples were genotyped using Illumina HumanHap 1M ( ), HumanHap 1M-Duo ( ), n p 368 n p 135 or Illumina HumanHap 550K ( ) Bead Chips. All samn p 12 ples were brought into a single BeadStudio file using the standard Illumina cluster file. For quality control purposes, any sample that had very low intensity or a very low call rate with Illumina cluster (!99%) was deleted. All SNPs that had a call frequency of !99% were put into a filter and reclustered (excluding those on the X chromosome). The reclustering step created SNP calling errors, but the following procedures were used to prevent the errant calls from being released in the final report: (1) the SNPs with a cluster separation value of !0.3 were deleted, and (2) any SNPs with a Het Excess value (an indicator of the quantity of excess heterozygote calls relative to expectations) between Ϫ1.0 and Ϫ0.1 or between 0.1 and 1.0 were deleted. The filter was then released, and any SNP with a call frequency of !99% was deleted. These procedures resulted in a success rate of genotyping calls ranging from 99.20% to 99.999%, and 1,212,217 SNPs were included in the analysis. Ten samples were excluded because of insufficient call rate.
Specification of sex check, cryptic relatedness check, low minor allele frequency check, Hardy-Weinberg equilibrium check, and a recheck of the genotyping quality were all performed as described elsewhere [1] , and no samples were omitted at these steps. A total of 129,723 SNPs were dropped because of a low minor allele frequency. We also required that all SNPs included in the study were successfully genotyped in at least 50% of the samples; hence, 202,676 SNPs were dropped at this point, many of which were those not genotyped on all of the chips.
We used the Illumina 1M and 1M-Duo Bead Chip data as input into the PennCNV program [8] , which allowed us to look at deletions (0 or 1 copy) compared with wild types (2 copies) and duplications (3 or 4 copies) compared with wild types (2 copies). Because of the complications of hemizygosity in males and X chromosome inactivation in females, this analysis was restricted to autosomes. In addition, to ensure that we worked with high-confidence copy number variations (CNVs), we excluded any CNV for which the difference in the log like- lihood between the most likely copy number state and the less likely copy number state was !10 (generated using the "conf" function in PennCNV). We limited our analysis to CNVs that occurred in at least 3 people (minor allele frequency, 10.003). Further quality control thresholds in PennCNV that were used are detailed in Ge et al [9] . In this analysis, 497 participants were included.
HLA-B allotypes were assigned by DNA sequencing, beginning with the amplification of genomic DNA using primers that flank exons 2 and 3. Polymerase chain reaction products were cleaned using Ampure (Beckman Coulter). The cleaned products were cycle sequenced on an ABI 9700. The cycle sequenced products were cleaned using CleanSEQ (Beckman Coulter) and then run on an ABI Prism 3730. Sequence analysis was performed using Assign (Conexio Genomics).
The EIGENSTRAT method [10] was used to control for population stratification. Assessment of population structure in 616 African Americans by use of the EIGENSTRAT method resulted in 73 statistically significant axes of stratification after the removal of 35 population outliers. The first axis made a larger contribution to the proportion of variation (0.6%) explained than the contribution made by the second axis (0.2%) and reflected the degree of African versus European ancestry in individuals. We therefore used only the first axis as a covariate in our association analyses, to control for population stratification.
Phenotype. Set point viral load was defined as (1) the mean viral load for samples with 2 or more viral load values that were collected at least 30 days apart, within 3 months to 3 years after seroconversion, and were within a 1 log range, similar to what was done in the previous study of determinants of set point in participants of European ancestry [1] , or (2) the first available viral load within 3-12 months after seroconversion, as long as there was a corresponding CD4 + T cell count of 1350 cells/mL. All viral loads were measured prior to the initiation of antiretroviral therapy. Viral loads from the 2 definitions were highly correlated ( ), and the first definition was pref-2 r p 0.74 erentially used when sufficient data were available.
Statistical analysis. Viral load at set point was used as a quantitative trait in a linear regression using additive allelic effects. Because previous studies have found that sex and age may be associated with viral load, these factors were used as covariates in the model [11, 12] . The first EIGENSTRAT axis was used to control for population stratification, and the cohort was also included in the model because of baseline differences between the 2 groups. Individual regressions for each SNP were performed using PLINK software (version 1.06) [13, 14] . The Bonferroni correction was used to control for multiple comparisons. Associations for which were Ϫ8 P ! 5 ϫ 10 considered to have genome-wide statistical significance.
All HLA-B allotypes were tested for association with viral load set point in a linear regression model and were also evaluated to determine whether they were responsible for associations observed for SNPs in the genome-wide SNP association analyses.
RESULTS
From the DoD HIV NHS cohort, 487 participants met the inclusion criteria and 471 were successfully genotyped. From the MACS cohort, 158 participants met the inclusion criteria and 145 were successfully genotyped. Thirty-five participants were dropped from the analysis because of the EIGENSTRAT correction for ancestry, and 66 participants were not included because their viral load results did not meet the definition of set point described in Methods, which left 515 participants in the final data set. Table 1 shows the baseline characteristics of participants in the DoD and MACS cohorts, as well as the Bead Chips that were used for genotyping. There were more women in the DoD cohort ( ), and participants in this cohort P p .006 were, on average, younger at seroconversion ( ); how-P ! .001 ever, there was no difference between the cohorts in mean set point viral load ( ). P p . 13 No single SNP had a genome-wide statistically significant association ( ) with viral load at set point. Table 2 Ϫ8 P ! 5 ϫ 10 lists the top 20 genome-wide associations with set point, and Table 3 lists the top 10 associations from the MHC region and the top 10 functional SNPs that are associated with set point. A functional SNP was defined as a SNP that would cause the gain or loss of a stop codon, would cause a nonsynonymous coding change, or occurred in a splice site.
The most statistically significant SNP in the MHC region for association with viral load set point in this African American cohort was rs2523608, located in the HLA-B gene (P p ) ( Figure 1A and Table 3 ). We found that the same Ϫ6 2.3 ϫ 10 SNP was also statistically significantly associated with HIV-1 set point in a large sample of individuals of European ancestry ( , corrected for age and sex) ( Figure 1B ). This Ϫ6 P p 1.1 ϫ 10 association remains nominally statistically significant (P p ) after accounting for variants in the MHC region that .0083 were previously shown to be associated with HIV-1 outcomes (rs2395029, rs9264942, and rs9261174) and 12 statistically significant EIGENSTRAT axes to control for population stratification in this cohort.
The rs2523608 variant is located in intron 5 (according to Ensembl transcript ENST00000376228), which is 1100 base pairs from the nearest exon. Analysis of the HLA-B allotypes from 285 genotyped study participants showed that this association was due to the association between rs2523608 and HLA-B*5703 ( ; ). equilibrium can be quantified using the D statistic [15] . This statistic compares the ancestral recombination patterns between 2 variants by standardizing allele frequencies. A value of indicates that 1 variant always appears on the back-D p 1 ground of the other. On the other hand, the r 2 statistic is sensitive to allele frequency differences and assesses the degree to which the 2 variants appear together [16, 17] . When considered alone, HLA-B*5703 had by far the strongest association with viral load set point of any HLA-B allotype, showing genomewide statistical significance ( , with age, sex, co-Ϫ10 P p 5.6 ϫ 10 hort, and 1 EIGENSTRAT axis as covariates) (Table 4 and Figure 1C) . Moreover, when HLA-B*5703 was included as a covariate, it was able to account for the effect of the rs2523608 genotype. This analysis shows that HLA-B*5703 is the most important common variant in influencing viral load in African Americans, explaining ∼10% of the variation in viral load set point in this data set, with an allele frequency of ∼4.0%.
CNV analysis. There were 8724 SNPs that showed evidence of a duplication and 16,778 SNPs that showed evidence of a deletion. The CNV calls for each SNP were then run as genotypes in a regression using an additive genetic model, testing for association with HIV-1 set point. Sex, cohort, and the first EIGENSTRAT axis were used as covariates. After a Bonferroni correction was applied ( for duplications and
Ϫ6 Ϫ6
6 ϫ 10 3 ϫ 10 for deletions), no SNPs reached genome-wide statistical significance for either deletions or duplications. Furthermore, when the association results from these 2 models were compared, there was no SNP associated with both deletions and duplications for which . P ! .05 Association with previously implicated variants. We also analyzed genetic variants that had previously been shown to have an effect on HIV-1 set point. First, we tested the association with rs2395029, a nonsynonymous SNP in the HCP5 gene that is a tag for the functional allele HLA-B*5701, and found this SNP to show a weak association with viral load set point ( ) P p .030 (Table 5) . This SNP has a very low minor allele frequency in African Americans (minor allele frequency, 0.008) because of its virtual absence in West African populations. Therefore, the power to detect an association in this cohort is only 81% at , P ! .05 assuming that the effect size in our cohort is comparable to that seen for individuals of European descent [1] .
We then tested the association with rs9264942, a CrT polymorphism that is 35 kilobases upstream of the HLA-C gene. This SNP itself is not causal, but it is a tagging SNP for an unknown causal variant or variants. We observed a weak association between rs9264942 and set point in African Americans ( ) (Table 5 ). P p .018 We also tested the associations between viral load at set point and rs9261174, a SNP located near the ZNRD1 gene in the MHC region, and CCR5-D32, a 32-base pair deletion in the CCR5 gene (rs333) that is rare in non-European populations. In our African American cohort, neither rs9261174 ( ) nor CCR5-D32 ( ) showed an association P p .352 P p .484 with viral load at set point (Table 5) .
DISCUSSION
To our knowledge, this was the first genome-wide association study on HIV-1 outcomes to be performed among an African American cohort, the majority of whom were infected with HIV-1 subtype B. We have shown that the intronic SNP rs2523608, the top associated SNP in the MHC region, is tagging HLA-B*5703. The value of D for the association between rs2523608 and HLA-B*5703 is 1, and a regression model shows that the HLA-B*5703 genotype is able to account for the effect of this intronic SNP. HLA-B*5703 is strongly associated with viral load at set point and reached whole-genome statistical significance in the subset of samples for which HLA-B allotype data were available ( , in a model that al-
Ϫ10
P p 5.6 ϫ 10 so included age, sex, cohort, and the first EIGENSTRAT axis;
). n p 285 HLA-B*5701 is an important mechanism of HIV-1 control in the European population. It had an allele frequency of ∼6.1% in a European population, but it was not observed in a Yoruban population [18] . Its close relative HLA-B*5703 was absent in a European population, but HLA-B*5703 had an allele frequency of ∼5.8% in a Yoruban population [18] . Here, we have shown that African American individuals who have HLA-B*5703 also show improved viral control, of a magnitude similar to that afforded by HLA-B*5701 in people of European descent. Thus, our results indicate that the general mechanism of genetic control of HIV-1 in African Americans is similar to that in Europeans: HLA-B*5701 accounts for ∼6% of the observed variation in viral load set point in Europeans [7] , and HLA-B*5703 accounts for ∼10% of the observed variation in viral load set point in African Americans. There was also a small contribution to HIV-1 control by HLA-B*5701 (frequency, 0.3%) in our African American data set, because of admixture.
We also found that HLA-B*3910 and HLA-B*1517, in addition to HLA-B*5703, may be playing a lesser role in viral control, although additional studies would be needed to confirm these observations. This pattern was similar to that observed in people of European descent, among whom HLA-B*5701 is the largest determinant of HIV-1 control but other HLA-B alleles (HLA-B*27, HLA-B*35, and others) also play a role [7] . The effects of the alleles that we have identified are further supported by an analysis of the MHC region that was conducted in southern African populations infected with HIV-1 subtype C, in which HLA-B*5703 was found to be the HLA class I allele most strongly associated with a decreased viral load set point [3, 19] , with a weaker contribution by HLA-B*39 [19] .
We found a reduced or absent association with viral load set point when we explicitly checked variants that had been shown to be associated with set point in a cohort of patients of European descent. Similar outcomes were seen in Shrestha et al [4] , who saw a reduced association between rs9264942 and set point and no association between rs2395029 and set point. Our sample size was 14 times larger than that in Shrestha et al [4] and revealed only weak associations between both variants and set point. So although both rs9264942 and rs2395029 are definitively associated with viral load set point in European populations, neither study was able to replicate these associations in an African American cohort.
It is worth noting that it is only the HLA-B*5701 association in the previous study [1] for which the causal site is thought to have been identified. In the cases of rs9264942 and rs9261174, it is likely that the associated variants are not themselves causal but rather markers of an as yet unidentified causal site or sites. It may therefore not be a coincidence that the HLA-B*57 association is the only one to show an effect in African Americans that is similar to that shown in individuals of European ancestry. For the other 2 associations, the different and generally lower linkage disequilibrium in this region in African Americans (Figure 2 ) could mean that the causal sites are no longer being tagged by these variants.
A potential limitation of this study is that HIV-infected persons with rapid disease progression may have been excluded. Rapid progressors may not have had many research visits and therefore may not have had enough cells in the repository to be included in this study. In addition, because of their rapid disease progression, they may not have had available viral load measurements that satisfied the definition of set point. Approximately 10% of the participants in this study progressed to a CD4 + cell count of !200 cells/mm 3 within 2 years after seroconversion; therefore, there were at least some rapid progressors included in this study.
Earlier studies have likewise suggested that HLA-B*5703 may also be involved in HIV-1 control in African Americans, but our study shows that it is indeed the most statistically significant common genetic factor affecting early viral control in this population. By using a genome-wide scan to implicate another allele of HLA-B*57 in HIV-1 control, in an ancestral background that was entirely different from that where this association had previously been observed, we provide further support for the important role played by HLA-B*57 in HIV-1 control and the decreased fitness level of the viral mutants that are selected for by HLA-B*57. Given the increased burden of disease in African and African American populations and the paucity of common variants that clearly influence HIV-1 control, it is important to continue to investigate rare variants that may function specifically in these populations.
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